Cliff Asness’s Foghorn Therapeutics FHTX Stock Holding History

Cliff Asness’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$323K	Buy	66,239 +33,679	+103%	+$149K	﹤0.01%	3598
2026 Q1	$156K	Buy	32,560 +19,010	+140%	+$104K	﹤0.01%	3639
2025 Q4	$73.2K	Sell	13,550 -4,228	-24%	-$19.2K	﹤0.01%	3485
2025 Q3	$86.9K	Sell	17,778 -80	-0.4%	-$424	﹤0.01%	3379
2025 Q2	$83.9K	Sell	17,858 -835	-4%	-$3.49K	﹤0.01%	3206
2025 Q1	$68.2K	Buy	+18,693	New	+$85.2K	﹤0.01%	3063
2023 Q1	–	Sell	-39,817	Closed	-$254K	–	2194
2022 Q4	$254K	Sell	39,817 -30,770	-44%	-$232K	﹤0.01%	2020
2022 Q3	$606K	Buy	+70,587	New	+$908K	﹤0.01%	1704

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cliff Asness's FHTX Position: Q2 2026 in Review

Cliff Asness increased its Foghorn Therapeutics (FHTX) stake by 103% in Q2 2026, buying an estimated $149K and bringing the position to 66,239 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #3598.

Cliff Asness first reported a position in FHTX in Q3 2022 and has held it in 8 quarters since. The position peaked at $606K in Q3 2022. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

Cliff Asness held 66,239 shares of Foghorn Therapeutics worth $323K as of Q2 2026.
Cliff Asness bought 33,679 Foghorn Therapeutics shares in Q2 2026, an estimated $149K.
Foghorn Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3598 holding.
Cliff Asness first reported a position in Foghorn Therapeutics in Q3 2022 and has held it in 8 quarters since.
Cliff Asness's Foghorn Therapeutics position peaked at $606K in Q3 2022.
102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.